Skip to main content
. 2019 Oct 8;3(19):2905–2910. doi: 10.1182/bloodadvances.2019000507

Table 1.

Various MP clinical trials

Trial no. Trial title Status
NCT02338050 Moxetumomab pasudotox in children with B-lineage acute lymphoblastic leukemia and minimal residual disease prior to allogeneic hematopoietic stem cell transplantation Terminated
NCT02227108 Study in pediatrics with relapsed or refractory pediatric acute lymphoblastic leukemia (pALL) or lymphoblastic lymphoma Terminated (lack of required efficacy in first 32 patients enrolled)
NCT01891981 Study of moxetumomab pasudotox in patients with relapsed and/or refractory acute lymphoblastic leukemia (ALL) Terminated (did not proceed to the phase II terminated early by the sponsor)
NCT00587457 A phase I, multicenter, dose escalation study of CAT-8015 in participants with chronic leukemia Terminated (the study is terminated early due to unavailability of investigational product)
NCT01030536 Safety study of CAT-8015 to treat advanced B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL or CLL) Terminated (prioritization of resources)